ReviewDrug delivery2022
Design and applications of liposome-in-gel as carriers for cancer therapy.
Review in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Nanovesicular Spanlastics Thermosensitive Gel for the Ocular Delivery of Voriconazole: Development, Ex Vivo Transcorneal Permeability, and In Vivo Evaluation in a Rabbit Model of Fungal Keratitis.AAPS PharmSciTech · 2026Article
- Hybrid Mucointeractive Delivery Systems-Alternative Approaches to Mucosal Delivery.Molecules (Basel, Switzerland) · 2026Review
- Novasomal Gel for Enhanced Dermal Delivery and Antibacterial Efficacy of Cinnamic Acid.Molecules (Basel, Switzerland) · 2026Article
- Dual-Stimuli Injectable Platforms for Localized Breast Cancer Therapy.Nano letters · 2026Review
- A 'two-in-one' tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues.Journal of nanobiotechnology · 2026Article
- Puerarin-Loaded Proniosomal Gel: Formulation, Characterization,Gels (Basel, Switzerland) · 2026Article
- Artesunate nanoliposome-hydrogel: a dual-modal therapy for post-surgical melanoma.Theranostics · 2026Article
- Preclinical advance in nanoliposome-mediated photothermal therapy in liver cancer.Lipids in health and disease · 2025Review
- Emerging role of exosomes in cancer therapy: progress and challenges.Molecular cancer · 2025Review
- Advances in Enzyme-responsive SupramolecularCurrent drug delivery · 2025Review
- The recent research progress in the application of the nanozyme-hydrogel composite system for drug delivery.Drug delivery · 2024Review
- A mucoadhesive-to-penetrating nanomotors-in-hydrogel system for urothelium-oriented intravesical drug delivery.Journal of nanobiotechnology · 2024Article
- Smart delivery vehicles for cancer: categories, unique roles and therapeutic strategies.Nanoscale advances · 2024Review
- Injectable hydrogel based on liposome self-assembly for controlled release of small hydrophilic molecules.Acta biomaterialia · 2024Article
- Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo.International journal of nanomedicine · 2024Article
- A Big Prospect for Hydrogel Nano-System in Glioma.International journal of nanomedicine · 2024Review
- Viscoelasticity of Liposomal Dispersions.Nanomaterials (Basel, Switzerland) · 2023Article
- Magnetic-Responsive Liposomal Hydrogel Membranes for Controlled Release of Small Bioactive Molecules-An Insight into the Release Kinetics.Membranes · 2023Article
- Research progress of nanovaccine in anti-tumor immunotherapy.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer has long been a hot research topic, and recent years have witnessed the incidence of cancer trending toward younger individuals with great socioeconomic burden. Even with surgery, therapeutic agents serve as the mainstay to combat cancer in the clinic. Intensive research on nanomaterials can overcome the shortcomings of conventional drug delivery approaches, such as the lack of selectivity for targeted regions, poor stability against degradation, and uncontrolled drug release behavior. Over the years, different types of drug carriers have been developed for cancer therapy. One of these is liposome-in-gel (LP-Gel), which has combined the merits of both liposomes and hydrogels, and has emerged as a versatile carrier for cancer therapy. LP-Gel hybrids have addressed the lack of stability of conventional liposomes against pH and ionic strength while displaying higher efficiency of delivery hydrophilic drugs as compared to conventional gels. They can be classified into three types according to their assembled structure, are characterized by their nontoxicity, biodegradability, and flexibility for clinical use, and can be mainly categorized based on their controlled release, transmucosal delivery, and transdermal delivery properties for anticancer therapy. This review covers the recent progress on the applications of LP-Gel hybrids for anticancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.